EMA might deny Merck's molnupiravir conditional marketing authorization — report
While Merck’s Covid-19 antiviral molnupiravir has been given EUA in the US, it has still been pending authorization in Europe. And according to a new report from the Financial Times, the EMA might not recommend granting conditional marketing authorization — potentially shutting Merck’s antiviral out of one of the world’s largest drug markets.
People familiar with the approval process told the news organization that the EMA is unlikely to grant conditional marketing authorization to Merck’s Covid-19 antiviral as it wrestles with “problematic” data.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.